Pooled efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials...

Long-term Safety and Efficacy of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild-to-Moderate Atopic Dermatitis: A...

Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age...

Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Disease Severity and Age Subgroups in the Treatment of Adults and Children Down...

Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: A post hoc analysis of ARCADIA 1 and 2 data Author: Jonathan I...

Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with...

Nemolizumab improves skin lesions, itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis: Results from two...

Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to 11 Years: Results From a Phase...

Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE...

Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis Authors: Andrew...

Atopic Dermatitis Disease Control Measured with the Recap of Atopic Eczema (RECAP) Instrument: The Real-World Impact of Disease...

A Checklist to Aid in Identifying Patients with Atopic Dermatitis who are Candidates for Systemic Therapy Authors: Jonathan Silverberg,...

Efficacy and Safety of Lebrikizumab is Maintained to Two Years in Patients with Moderate-to-Severe Atopic Dermatitis Authors: Emma...

Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Not Adequately Controlled or Non-Eligible...

Interim Results from Admirable, A Phase 3b Open-Label Study Assessing Lebrikizumab in Patients with Skin of Color and Moderate-to-Severe...

Impact of Baseline Disease Severity on the Long-Term Efficacy of Abrocitinib Treatment in Patients With Moderate-To-Severe Atopic...

Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b...

Growth Analysis in Children Aged Less Than 12 Years with Moderate-to-Severe Atopic Dermatitis Authors: Amy S Paller, Bob Geng, Alan...

Dupilumab Treatment Reduces Signs in Patients with Atopic Hand and Foot Dermatitis: Results From a Phase 3, Randomized, Double-blind,...

Dupilumab Improves Health-Related Quality of Life and Work Productivity Among Adults With Moderate-to-Severe Atopic Dermatitis in...